Prophylactic (preventive) treatment for hemophilia AÂ and B is generally more effective than on-demand treatment in reducing the frequency…
Articles by Margarida Maia, PhD
World Hemophilia Day is April 17, and this year it will focus on the challenges of women and girls living…
Takeda Pharmaceuticals has decided to discontinue Hemofil M (human antihemophilic factor) and Recombinate (recombinant antihemophilic factor), both of…
An experimental gene therapy using modified blood stem cells helped five adults with severe hemophilia A attain therapeutic levels…
Sangamo Therapeutics will regain full rights to develop and market giroctocogene fitelparvovec, a gene therapy candidate for adults…
In 2024, Hemophilia News Today provided readers with up-to-date coverage on research, treatments, and clinical trials for hemophilia.
For adults and adolescents with hemophilia A without inhibitors, Altuviiio (efanesoctocog alfa) may work better than other standard…
Adults and adolescents with hemophilia A or hemophilia B without inhibitors experienced significantly fewer bleeding episodes when using…
Pfizer’s Hympavzi (marstacimab) has been approved in the European Union (EU) to prevent or reduce the frequency of bleeding…
Hympavzi (marstacimab-hncq) may be available by prescription in the U.S. before the end of the year. The therapy was…